Talis Biomedical Corporation (TLIS)

Talis Biomedical Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Cash & Equivalents	76.73	130.19	232.55	173.13	21.6
Cash & Cash Equivalents	76.73	130.19	232.55	173.13	21.6
Cash Growth	-41.06%	-44.01%	34.32%	701.39%	213.33%
Receivables	0.05	0.31	0.18	0.47	1.81
Other Current Assets	0.9	2.78	3.39	15.12	0.7
Total Current Assets	77.68	133.28	236.12	188.72	24.11
Property, Plant & Equipment	15.45	34.23	23.44	9.68	1.54
Other Long-Term Assets	1.54	1.78	6.28	0	0.09
Total Long-Term Assets	16.99	36.01	29.71	9.68	1.63
Total Assets	94.67	169.29	265.83	198.41	25.73
Accounts Payable	1.34	3.77	5.12	4.91	1.57
Current Debt	2.88	3.7	1.23	0.69	0
Other Current Liabilities	4.55	5.2	12.75	10.43	2.47
Total Current Liabilities	8.77	12.67	19.11	16.03	4.04
Long-Term Debt	16.79	29.88	12.75	0	0
Other Long-Term Liabilities	0	0	0	0	0.08
Total Long-Term Liabilities	16.79	29.88	12.75	0	0.08
Total Liabilities	25.56	42.55	31.85	16.03	4.12
Total Debt	19.67	33.58	13.98	0.69	0
Debt Growth	-41.43%	140.27%	1916.88%	-	-
Retained Earnings	-539.96	-477.95	-364.94	-172.91	-81.78
Shareholders' Equity	69.12	126.74	233.98	-108.57	-21.14
Net Cash / Debt	57.06	96.61	218.57	172.44	21.6
Net Cash / Debt Growth	-40.93%	-55.80%	26.75%	698.19%	213.33%
Net Cash Per Share	31.40	53.66	144.71	1219.91	150.68
Working Capital	68.91	120.61	217.01	172.69	20.07
Book Value Per Share	38.03	70.39	154.91	-768.07	-412.69

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).